ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1597

Use of a Clinical Dashboard Improves the Documentation of Disease Severity Scores and May Facilitate the Implementation of Treat to Target Therapy

Taylor Nelson1, Gary Kunkel2 and Grant Cannon2, 1University of Utah, Salt Lake City, 2Salt Lake City VA Medical Center and University of Utah, Salt Lake City

Meeting: ACR Convergence 2020

Keywords: Decision analysis, Disease Activity, informatics, Measurement Instrument, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Measures & Measurement of Healthcare Quality Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid Arthritis (RA) management guidelines recommend the collection of Disease Activity Measures (DAMs) to direct therapy as a component of a “treat-to-target” (T2T) strategy.  A goal of the Veterans Affairs Rheumatoid Arthritis (VARA) registry is to systematically collect 6 clinical DAMs and two laboratory DAMs at each visit using note templates (Table 1).  The real-time calculation of disease severity scores such as DAS28 is not part of the standard VARA protocol.  We developed an on-line clinical dashboard that collects real-time DAMs and displays them longitudinally to calculate disease activity scores including DAS28 in real-time.  In this study, we evaluated the association of clinical dashboard utilization with 1) DAS28 capture in the medical record and 2) the frequency of major changes in RA therapy.

Methods: Clinical notes from initial clinic visits for each US Veteran enrolled in VARA from a single site (between 10/2012 and 6/2018 – when the dashboard became available) were evaluated for documentation of 8 possible DAMs and whether major therapeutic changes (MTCs) were undertaken. We compared clinic notes for visits where the clinical dashboard was deployed for data collection with visits where the clinical dashboard was not used. MTC was defined as: initiation of synthetic or biologic disease-modifying antirheumatic drug (DMARD); DMARD dose escalation ≥25%; prednisone use (new agent or after 90-day gap); prednisone dose increased 25%; and/or corticosteroid injection in ≥2 joints.  We also recorded changes and/or escalation in therapy even if it did not meet MTC criteria.  Each MTC or lack of MTC was classified as being consistent or not consistent with ACR guidelines and our previously published potential optimal DAS28 threshold for MTC (See Table 2 Footnote).

Results: The 146 RA patients with a visit using the dashboard were similar to the 201 patients in whom the dashboard was not used referent to age, disease duration, clinical RA features, DAMs and overall DAS28 (Table 1).  Clinic notes for patient visits using the dashboard were significantly more likely to record a DAS28 (75.3%) than visits not using the dashboard (2.0%) (p< 0.001)  (Table 2).  There was no significant difference in likelihood of an MTC, (20.5% vs 16.4%) or any therapeutic escalation (33.6% vs 27.4%) (Table 2).  Management decisions to escalate therapy as recommended in ACR guidelines were more common at DAS28 >3.2 threshold for change (70.5% vs 60.2%, p=0.046) and DAS28 >3.8 threshold for change (77.4% vs. 66.7%, p=0.029).

Conclusion: Utilization of a clinical dashboard can improve documentation of disease activity scores such as DAS28 in real time. Further study is needed to determine if the use of a clinical dashboard will improve the implementation of care that is concordant with best practices and whether this leads to improvements in long-term patient outcomes.


Disclosure: T. Nelson, None; G. Kunkel, None; G. Cannon, Amgen, Inc., 2, Merck, 2.

To cite this abstract in AMA style:

Nelson T, Kunkel G, Cannon G. Use of a Clinical Dashboard Improves the Documentation of Disease Severity Scores and May Facilitate the Implementation of Treat to Target Therapy [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/use-of-a-clinical-dashboard-improves-the-documentation-of-disease-severity-scores-and-may-facilitate-the-implementation-of-treat-to-target-therapy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/use-of-a-clinical-dashboard-improves-the-documentation-of-disease-severity-scores-and-may-facilitate-the-implementation-of-treat-to-target-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology